Analyst Jason Zemansky of Bank of America Securities maintained a Buy rating on Werewolf Therapeutics (HOWL – Research Report), with a price target of $10.00.
Jason Zemansky of Bank of America Securities has given Werewolf Therapeutics’s stock (HOWL) a Buy rating based on a combination of factors. The most critical of these are the encouraging initial safety updates from Werewolf’s ongoing phase 1/1b of IL-2 prodrug ‘124. The updates indicate no instances of capillary leak syndrome, a common issue with IL-2, which is a testament to the effectiveness of the company’s proprietary technology designed to mask the molecule until activated within the Tumor Microenvironment (TME).
Zemansky also notes the potential of Werewolf’s platform, which is backed by the well-established efficacy of cytokines and exciting pre-clinical updates. While further insights are needed, including evidence of ‘124 activation within the TME, Zemansky continues to see a compelling upside for the molecule. He cites extended dosing intervals, out-patient administration, expansion of treatment populations beyond RCC and melanoma, and extended combination opportunities with Immunotherapy (I/O) and other Standards of Care (SoC) as reasons for maintaining the Buy rating.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Werewolf Therapeutics (HOWL) Company Description:
Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.
Read More on HOWL:
- Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
- Werewolf Therapeutics to Participate in Upcoming Investor Conferences
